China Has Plenty of Cancer Guidelines but Too Few Reach the Clinic

China has produced a strikingly large number of clinical practice guidelines for cancer care over the past decade, yet many of these documents never translate into consistent treatment at the bedside. That paradox is the central argument of a Policy Forum published in PLOS Medicine, in which a team of Chinese and international researchers examines why oncology guidelines in China have multiplied in quantity while remaining fragmented in quality, accessibility, and real-world use. The authors, led by Minzhi Lv of Zhongshan Hospital, Fudan University, and Tianshu Liu, argue that the core problem is not a shortage of guidelines but the absence of an integrated governance and implementation ecosystem linking guideline development, dissemination, and clinical practice.

The scale of the underlying disease burden is considerable. In 2022, approximately 20 million new cancer cases and nearly 9.7 million cancer deaths occurred globally, with China accounting for roughly one quarter of that burden, according to figures cited in the analysis. At the same time, the rapid expansion of targeted therapy, immunotherapy, and other emerging treatment modalities has substantially increased the complexity of oncology decision-making, making clinical practice guidelines an increasingly important tool for synthesising evidence, reducing unwarranted variation, and supporting equitable care.

Oncology guideline development in China began relatively late, initially relying on expert consensus and adaptation of international guidelines before shifting toward domestically led production. Over the past decade, the number and scope of oncology guidelines have grown rapidly, with coverage expanding across tumour types and increasingly incorporating precision medicine and whole-course management. The Chinese Society of Clinical Oncology alone published 186 guidelines between 2016 and 2025, while the China Anti-Cancer Association guideline programme, running from 2022 to 2025, covered 53 cancer types and 72 treatment modalities, totalling 125 guidelines. Yet the authors contend that this quantitative expansion has been accompanied by increasing disintegration in how guidelines are produced.

Fragmentation begins at the top. Guidelines are issued by the National Health Commission and by major professional societies, including the Chinese Society of Clinical Oncology, the China Anti-Cancer Association, and branches of the Chinese Medical Association, each operating its own programme. A systematic review of 2,654 Chinese clinical practice guidelines found that 71.1 percent were developed by medical specialty societies and only 2.6 percent by government agencies. The authors note that the functional boundaries and hierarchy among these bodies remain insufficiently defined, and overlapping mandates may reinforce incentives to maintain parallel guideline systems. As a result, guidelines addressing the same type of cancer can coexist with differences in scope, treatment pathways, and evidence interpretation, creating uncertainty for clinicians.

Methodological rigour also varies widely. Evaluations using the AGREE II and RIGHT reporting checklists consistently show wide variation across tumour types and issuing organisations, although some Chinese oncology guidelines demonstrate methodological quality comparable to international standards. Many guidelines lack systematic evidence grading using the GRADE framework or transparent evidence synthesis, and non-evidence-based consensus statements developed with less rigorous methodology further compound concerns about the quality of the evidence base. The authors point out that this is not a uniquely Chinese problem: analyses of American Society of Clinical Oncology guidelines have also identified strong recommendations supported by low-quality evidence, particularly among consensus-based recommendations. Guideline developers in China have additionally used heterogeneous systems for grading evidence and formulating recommendation strength, which may complicate cross-guideline interpretation and clinical application.

Gaps in high-quality domestic evidence matter most for digestive cancers that impose a substantial disease burden in China, including gastric and hepatobiliary malignancies. In biliary tract cancers, for example, most China-specific evidence on systemic and emerging combination therapies comes from relatively small retrospective or real-world cohorts, while prospective data on some targeted and immune therapies remain limited. Structural misalignment between guideline development and real-world clinical contexts further undermines applicability: many guidelines are based primarily on the practice of large urban hospitals, with limited consideration of resource-constrained settings, reducing applicability at lower levels of care. Timely updating is another persistent weakness. As of December 2012, only 10 percent of 380 Chinese guidelines had ever been revised, with average update intervals exceeding five years, although the situation has improved in recent years, particularly in oncology, where major guidelines such as those issued annually by the Chinese Society of Clinical Oncology are updated more frequently.

Transparency and conflict-of-interest management remain insufficient as well. AGREE II assessments show low scores in the domain of editorial independence and conflict-of-interest disclosure. In the systematic review of 2,654 Chinese guidelines, only 18.6 percent reported conflicts of interest, only 1.36 percent described methods for collecting and reviewing such information, and none provided publicly accessible conflict-of-interest statements for all authors. The authors argue that these gaps extend beyond disclosure itself to the standardisation of conflict identification, review and management procedures, public accessibility of individual declarations, and independent oversight.

Even well-developed guidelines face a persistent knowledge-to-practice gap. Dissemination in China relies mainly on official websites, academic conferences, journal publications, and printed books, formats that work well for specialists in large urban hospitals but offer limited reach and high access barriers for clinicians in primary and secondary care. Conferences are constrained by scale and geography, journals are often behind paywalls, and printed materials are costly and quickly outdated. Clinicians in primary-level settings show low awareness and utilisation of guidelines, relying largely on informal access routes such as institutional distribution or public search engines. In one colorectal cancer-specific survey, awareness of the international National Comprehensive Cancer Network guidelines exceeded 90 percent despite the availability of multiple domestic guidelines, an imbalance the authors attribute partly to disparities in dissemination strategies, format accessibility, and supporting educational resources. Compared with major international organisations, Chinese guideline developers have been slower to adopt diversified dissemination approaches such as mobile platforms, interactive tools, and patient-oriented materials.

Implementation barriers compound the dissemination problem. Available evidence from China and other settings suggests substantial gaps between recommendations and practice. In one multi-center study of 1,828 patients with non-small cell lung cancer across 20 hospitals in Liaoning Province, only 36.7 percent received both guideline-concordant diagnosis and treatment, which was associated with a 29 percent lower risk of lung cancer mortality. Barriers operate at multiple levels: clinicians face heavy workloads, limited formal training in evidence-based medicine, and entrenched practice habits, while some worry that guidelines may promote so-called cookbook medicine. Patient-level factors, including limited understanding of treatment benefits and risks, financial constraints, and treatment refusal, further complicate adherence. At the systemic level, most oncology guidelines remain purely advisory, and structural tensions with healthcare financing mechanisms, notably the National Tertiary Public Hospital Performance Appraisal and the DRG and DIP case-based payment models, create incentives to contain costs that are not necessarily aligned with clinical guideline recommendations, so strict adherence to advanced, resource-intensive recommendations may place hospitals under financial or performance pressure.

To address these systemic gaps, the authors propose a four-part strategic framework. First, they call for a national joint clearinghouse and registration system, led by the National Health Commission, requiring prospective registration of guideline topics and planned updates, with an open-access National Oncology Guideline Clearinghouse overseen by the National Center for Medical Quality Control, independent third-party methodological evaluation, and explicit sunset criteria for outdated guidelines. Second, they recommend integrating resource-stratified pathways, categorised into basic, core, and enhanced tiers, with locally relevant evidence, defining minimum institutional capabilities and explicit referral thresholds for complex interventions. Third, they urge expansion of free, diversified dissemination channels, including digital platforms and artificial intelligence-based clinical decision-support systems, which the Chinese Society of Clinical Oncology has already begun exploring, alongside tiered training programmes. Fourth, they propose embedding implementation science into routine oncology care and aligning quality metrics with healthcare financing, including adaptive payment mechanisms within DRG and DIP frameworks and a shift in hospital performance appraisal toward quality-adjusted, value-based metrics. The authors emphasise that further empirical research is needed to evaluate cancer-specific and regional differences in guideline implementation and outcomes, and that China’s experience may offer lessons for other middle-income health systems facing rapid technological change, fragmented service delivery, and persistent inequities in cancer care.

Subject of Research: Governance, dissemination, and implementation challenges of oncology clinical practice guidelines in China

Article Title: Challenges and recommendations for implementation of oncology clinical practice guidelines in China

Article References: Lv, M., Yuan, D., Suo, Y., Ding, F., Hu, L., Cao, L., Wang, Y., Lei, J., Tang, S., & Liu, T. (2026). Challenges and recommendations for implementation of oncology clinical practice guidelines in China. PLOS Medicine, 23(10), e1005261. https://doi.org/10.1371/journal.pmed.1005261

Image Credits: AI Generated

DOI: 10.1371/journal.pmed.1005261

Keywords: clinical practice guidelines, oncology, China, health policy, guideline implementation, dissemination, conflict of interest, DRG payment, health systems, evidence-based medicine, PLOS Medicine, cancer care